Purpose: Anaplastic thyroid cancer (ATC) is a deadly form of thyroid cancer. V600E is the only actionable mutation for which there is a Food and Drug Administration-approved drug combination. Rapid detection of V600E and initiation of therapy is critical.
View Article and Find Full Text PDFMedullary thyroid carcinoma (MTC), an aggressive form of thyroid cancer, occurs sporadically in approximately 75% of MTCs. and mutations play a role in about 40% and 15%, respectively, of sporadic MTCs and are predominant drivers in MTC pathways. These mutations are some of the most comprehensively described and screened for in MTC patients; however, in recent studies, other mutations in the gene (p18) have been implicated in the tumorigenesis of MTC.
View Article and Find Full Text PDF